$26.49
1.07% yesterday
Nasdaq, Dec 20, 10:01 pm CET
ISIN
US10806X1028
Symbol
BBIO
Sector
Industry

BridgeBio Pharma Inc Stock price

$26.49
+3.45 14.97% 1M
-0.56 2.07% 6M
-13.88 34.38% YTD
-11.71 30.65% 1Y
-14.95 36.08% 3Y
-15.05 36.23% 5Y
-1.06 3.85% 10Y
Nasdaq, Closing price Fri, Dec 20 2024
+0.28 1.07%
ISIN
US10806X1028
Symbol
BBIO
Sector
Industry

Key metrics

Market capitalization $5.01b
Enterprise Value $6.34b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 29.12
P/S ratio (TTM) P/S ratio 22.99
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 2,209.77%
Revenue (TTM) Revenue $217.77m
EBIT (operating result TTM) EBIT $-532.70m
Free Cash Flow (TTM) Free Cash Flow $-451.54m
Cash position $405.73m
EPS (TTM) EPS $-2.41
P/E forward negative
P/S forward 22.83
EV/Sales forward 28.92
Short interest 13.81%
Show more

Is BridgeBio Pharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,892 stocks worldwide.

BridgeBio Pharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a BridgeBio Pharma Inc forecast:

15x Buy
88%
2x Hold
12%

Analyst Opinions

17 Analysts have issued a BridgeBio Pharma Inc forecast:

Buy
88%
Hold
12%

Financial data from BridgeBio Pharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
218 218
2,209% 2,209%
100%
- Direct Costs 7.49 7.49
3% 3%
3%
210 210
9,635% 9,635%
97%
- Selling and Administrative Expenses 230 230
86% 86%
106%
- Research and Development Expense 506 506
22% 22%
233%
-526 -526
2% 2%
-242%
- Depreciation and Amortization 6.29 6.29
4% 4%
3%
EBIT (Operating Income) EBIT -533 -533
2% 2%
-245%
Net Profit -439 -439
28% 28%
-202%

In millions USD.

Don't miss a Thing! We will send you all news about BridgeBio Pharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

BridgeBio Pharma Inc Stock News

Neutral
GlobeNewsWire
8 days ago
PALO ALTO, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorization in the European Union (EU) for acoramidis for the treatmen...
Neutral
GlobeNewsWire
18 days ago
SANTA CRUZ, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Unnatural Products, Inc. (UNP), a biotech developing orally-delivered macrocyclic peptides to address previously undruggable targets, announced today that BridgeBio Pharma, Inc. (Nasdaq: BBIO), has exercised its option to license macrocyclic peptide candidates discovered using UNP's AI-enabled massively parallel chemistry platform.
Positive
Investors Business Daily
26 days ago
BridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted.
More BridgeBio Pharma Inc News

Company Profile

BridgeBio Pharma, Inc. is a pharma company. The firm engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.

Head office United States
CEO Neil Kumar
Employees 550
Founded 2015
Website www.bridgebio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today